NCT05247268
Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 8 versions: 7 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 15 words Show 4 more changesShow less
- Enrollment closed, study ongoing
- Secondary endpoints: details revised at 2 of 7 entries
- Site details revised
- Publications: details revised at 22 of 22 entries
- Notable Primary completion date: Mar 10, 2025 to Mar 10, 2027
- Study completion date: Mar 10, 2025 to Sep 10, 2027
- Minor Site details revisedv5
- Notable Primary completion date: Mar 10, 2024 to Mar 10, 2025v4
- Minor Primary completion date: Mar 1, 2024 to Mar 10, 2024
- Study completion date: Mar 1, 2025 to Mar 10, 2025
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Mar 1, 2022 to Mar 11, 2022
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (7)
Show 2 moreShow less
Arms and interventions
Patients will be stratified into BMI≥28kg/m2 group and BMI\<28kg/m2 group. Patients in BMI≥28kg/m2 or BMI\<28kg/m2 group will be randomly assigned (1:1) to GnRHa+letrozole group or MA/MPA group. Patients who will be assigned to GnRHa+letrozole group will receive triprorelin acetate (intramuscular injection of 3.75mg was given 4 weeks apart and the maximum use are 6 courses) plus letrozole (2.5mg oral daily and no more than 24 weeks). Then every 3 months, an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.
Patients will be stratified into BMI≥28kg/m2 group and BMI\<28kg/m2 group. Patients in BMI≥28kg/m2 or BMI\<28kg/m2 group were randomly assigned (1:1) to GnRHa+letrozole group or MA/MPA group.Patients assigned to MA/MPA group will receive MA/MPA (160 mg oral MA daily or 500 mg oral MPA daily).Then every 3 months, an hysteroscopy will be used to evaluate the endometrial condition, and the findings will be recorded.
Drugs: Megestrol Acetate 160 MG Oral Tablet, Medroxyprogesterone Acetate 500 MG, Triprorelin Acetate, Letrozole 2.5mg
Sites
1 site in 1 country
- Obstetrics and Gynecology Hospital, Fudan UniversityShanghai, China